Verseon

Edison Liu, MD, President Emeritus of the Jackson Laboratory, Joins Verseon's Scientific Advisory Board

Retrieved on: 
Wednesday, February 7, 2024
Book, Verseon, National Cancer Institute, Genetic distance, MD, Therapy, HUGO, Human Genome Organisation, JAX, Drug development, Genomics, Biology, Cancer, Pharmaceutical industry

FREMONT, Calif., Feb. 7, 2024 /PRNewswire/ -- Verseon is pleased to announce that Edison Liu, MD, President and CEO Emeritus of the Jackson Laboratory (JAX), has joined the company's scientific advisory board. Dr. Liu is an award-winning international expert in cancer biology, functional genomics, and translational medicine.

Key Points: 
  • FREMONT, Calif., Feb. 7, 2024 /PRNewswire/ -- Verseon is pleased to announce that Edison Liu, MD, President and CEO Emeritus of the Jackson Laboratory (JAX), has joined the company's scientific advisory board.
  • As JAX's CEO, Dr. Liu significantly grew the organization's international presence, research scope, and physical footprint.
  • Dr. Liu is a welcome addition to Verseon's scientific advisory board.
  • As we pursue multiple breakthrough treatments for cancer, we look forward to his contributions on Verseon's advisory board."

Verseon Gains US Patent Protection for Compounds that Could Eliminate Bleeding Risks of Current Anticoagulants

Retrieved on: 
Wednesday, January 24, 2024
Risk, Stroke, Bleeding, Protease, Patent, Patient, Verseon, Splenic infarction, Anticoagulant, Cardiovascular disease, CSO, Pharmaceutical industry

FREMONT, Calif., Jan. 24, 2024 /PRNewswire/ -- Verseon is pleased to announce that the USPTO has issued a new patent, "Thrombin Inhibitors, Formulations, and Uses Thereof," that further extends intellectual property protection for Verseon's novel class of thrombin inhibitors. These anticoagulant compounds promise to open new and safer treatment options for many of the world's 400+ million cardiovascular disease patients.

Key Points: 
  • These anticoagulant compounds promise to open new and safer treatment options for many of the world's 400+ million cardiovascular disease patients.
  • Unlike current anticoagulants, Verseon's Precision Oral Anticoagulants (PROACs) covered by this patent exhibit a unique mechanism of action that does not increase the risk of bleeding yet prevents the formation of the dangerous blood clots behind heart attacks and strokes.
  • Because these compounds are also highly selective against other serine proteases, they are expected to cause fewer side effects.
  • "We are pleased by the USPTO's decision to grant additional patent protection for our PROACs," said Verseon's CSO David Kita.

Verseon Pioneers Real-time Explainable AI

Retrieved on: 
Thursday, December 7, 2023
Drug discovery, Machine learning, Extreme, Health, AI, Verseon, Algorithm, Computational intelligence, ELM, Extreme learning machine, Medical device

FREMONT, Calif., Dec. 7, 2023 /PRNewswire/ -- Verseon is pleased to announce the publication of its peer-reviewed paper "X-ELM: A Fast Explainability Approach for Extreme Learning Machines" in Advances in Computational Intelligence. The company's X-ELM approach provides an accurate, real-time solution to an increasingly important problem in AI modeling – how to explain AI decision making.

Key Points: 
  • The company's X-ELM approach provides an accurate, real-time solution to an increasingly important problem in AI modeling – how to explain AI decision making.
  • Being able to interpret an AI model's decisions is vital in many mission-critical real-world AI applications.
  • The most advanced alternative to date, SHAP, is highly computationally intensive and takes days to yield results, rendering SHAP-based explainable AI impractical in day-to-day applications.
  • Verseon's X-ELM brings real-time explainability to a range of AI algorithms called Extreme Learning Machines (ELM).

Nobel Laureate Hartmut Michel Joins Verseon's Scientific Advisory Board

Retrieved on: 
Thursday, November 9, 2023
Royal Society, University of Frankfurt Institute for Social Research, Nobel Prize in Chemistry, Max Planck Institute of Biophysics, Foreign, Verseon, Research, German Academy of Sciences at Berlin, German National Academy of Sciences Leopoldina, American Physical Society, Biophysics, Science, University, Max Planck Society, Nobel Prize, Leibniz Prize, Cancer, Tuberculosis, Vaccine, Chemistry

FREMONT, Calif., Nov. 9, 2023 /PRNewswire/ -- Verseon is pleased to announce that Dr. Hartmut Michel, winner of the 1988 Nobel Prize in Chemistry, has joined the company's scientific advisory board. Dr. Michel's work in X-ray crystallography established methodologies for crystallizing cellular membrane proteins and elucidating their structures.

Key Points: 
  • FREMONT, Calif., Nov. 9, 2023 /PRNewswire/ -- Verseon is pleased to announce that Dr. Hartmut Michel, winner of the 1988 Nobel Prize in Chemistry, has joined the company's scientific advisory board.
  • Dr. Michel is a recipient of the Biophysics Prize of the American Physical Society and is one of the original eleven recipients of the Gottfried Wilhelm Leibniz Prize , the highest honor awarded in German scientific research.
  • Verseon's team is excited to have Dr. Michel join the company's scientific advisory board.
  • We are honored to have him on our advisory board."

Nobel Laureate Hartmut Michel Joins Verseon's Scientific Advisory Board

Retrieved on: 
Wednesday, November 8, 2023
Royal Society, University of Frankfurt Institute for Social Research, Nobel Prize in Chemistry, Royal Netherlands Academy of Arts and Sciences, Foreign, Verseon, Research, German Academy of Sciences at Berlin, German National Academy of Sciences Leopoldina, American Physical Society, Biophysics, Science, University, Nobel Prize, Leibniz Prize, Cancer, Tuberculosis, Vaccine, Chemistry

FREMONT, Calif., Nov. 8, 2023 /PRNewswire/ -- Verseon is pleased to announce that Dr. Hartmut Michel, winner of the 1988 Nobel Prize in Chemistry, has joined the company's scientific advisory board. Dr. Michel's work in X-ray crystallography established improved methodologies for crystallizing cellular membrane proteins and elucidating their structures.

Key Points: 
  • FREMONT, Calif., Nov. 8, 2023 /PRNewswire/ -- Verseon is pleased to announce that Dr. Hartmut Michel, winner of the 1988 Nobel Prize in Chemistry, has joined the company's scientific advisory board.
  • Among the many awards and prizes Dr. Michel has received are the Biophysics Prize of the American Physical Society and the Gottfried Wilhelm Leibniz Prize , the highest honor awarded in German scientific research.
  • Verseon's team is excited to have Dr. Michel join the company's scientific advisory board.
  • We are honored to have him on our advisory board."

Preventing Strokes and Heart Attacks Doesn't Have to Come with the Risk of Life-threatening Bleeding

Retrieved on: 
Sunday, December 18, 2022
Anticoagulant, Cardiovascular disease, European Journal, Bleeding, Embolism, Infarction, Stroke, Hospital, Pharmacology, ProAc, Holy Grail, Death, Medicinal chemistry, Verseon, Thrombin, Disability, Research, Disease, Cancer, European Journal of Medicinal Chemistry, Patient, Pharmaceutical industry

Hundreds of millions of patients worldwide need anticoagulants to prevent clots that lead to life-threatening events like strokes, heart attacks, and pulmonary embolisms.

Key Points: 
  • Hundreds of millions of patients worldwide need anticoagulants to prevent clots that lead to life-threatening events like strokes, heart attacks, and pulmonary embolisms.
  • Developing drugs that prevent unwanted clots while preserving the body's ability to stop excessive bleeding is the "Holy Grail" of anticoagulant drug programs.
  • Verseon is developing a new generation of anticoagulants called PROACs (Precision Oral Anticoagulants) that address this significant unmet medical need.
  • Verseon also has a second anticoagulant development candidate, VE-2851, which is expected to enter clinical trials at a later date.

Preventing Strokes and Heart Attacks Doesn't Have to Come with the Risk of Life-threatening Bleeding

Retrieved on: 
Wednesday, December 14, 2022
ProAc, Anticoagulant, Verseon, Pharmacology, European Journal, Hospital, Stroke, Patient, Disability, Holy Grail, Research, Death, Cardiovascular disease, Thrombin, Disease, Bleeding, Cancer, Embolism, Infarction, Pharmaceutical industry

FREMONT, Calif., Dec. 14, 2022 /PRNewswire/ -- Verseon is delighted to announce that the European Journal of Medicinal Chemistry has published a paper describing the company's groundbreaking research that led to promising novel drug candidates for cardiovascular disease. Cardiovascular disease is the leading cause of death and disability in the world. Hundreds of millions of patients worldwide need anticoagulants to prevent clots that lead to life-threatening events like strokes, heart attacks, and pulmonary embolisms.

Key Points: 
  • Hundreds of millions of patients worldwide need anticoagulants to prevent clots that lead to life-threatening events like strokes, heart attacks, and pulmonary embolisms.
  • Developing drugs that prevent unwanted clots while preserving the body's ability to stop excessive bleeding is the "Holy Grail" of anticoagulant drug programs.
  • Verseon is developing a new generation of anticoagulants called PROACs (Precision Oral Anticoagulants) that address this significant unmet medical need.
  • Verseon also has a second anticoagulant development candidate, VE-2851, which is expected to enter clinical trials at a later date.

Verseon Acquires Edammo

Retrieved on: 
Tuesday, October 18, 2022
Method, Verseon, Disease, Medicine, Machine learning, Intelligence, Degenerative disease, Biology, Data, Google, Eye, Technology, Cancer, Deep learning, Hereditary angioedema, Acquisition, AI, Diabetic retinopathy, Diabetes, Lists of diseases, Chemistry, Automated machine learning, Extreme, Pharmaceutical industry, Medical device

FREMONT, Calif., Oct. 18, 2022 /PRNewswire/ -- Verseon International Corporation, the company leading a technology-driven transformation of the pharmaceutical industry, announces that it has acquired Edammo, Inc.

Key Points: 
  • Verseon has continued to develop its own specialized AI tools internally to handle these situations.
  • Edammo's CEO Ed Ratner added, "We are pleased that Verseon determined our Extreme AutoML will enhance the machine-learning components of Verseon's platform.
  • Using its unique physics-augmented AI platform, Verseon is rolling out a steady stream of life-changing medicines.
  • Edammo takes a revolutionary approach to leveraging artificial intelligence to make real-time, data-driven decisions across multiple industries, including medicine and the life sciences.

Dr. Sangtae Kim to Lead Verseon's New AI and Data-Science Initiative as CTO

Retrieved on: 
Wednesday, January 12, 2022
Biological engineering, Chemical engineering, Research, CTO, BS, NSF, American Institute of Chemical Engineers, Science, Collection, Ho-Am Prize in Engineering, Morgridge Institute for Research, CEO, American Institute for Medical and Biological Engineering, Drug design, Hereditary angioedema, Government, Eli Lilly, Lists of diseases, Distinguishing, Initiative, Warner–Lambert, Ho-Am Prize in Science, National Academy of Engineering, University of Wisconsin–Madison, American Institute, William O. Baker Award for Initiatives in Research, Drug development, Doctor of Philosophy, National, AI, Verseon, Medicine, National academy, Sang, University, Diabetic retinopathy, Microfluidics, Pharmaceutical industry, Management, Engineering, Purdue University, California Institute of Technology

FREMONT, Calif., Jan. 12, 2022 /PRNewswire/ -- Verseon is pleased to announce the appointment of its new CTO, Dr. Sangtae (Sang) Kim.

Key Points: 
  • FREMONT, Calif., Jan. 12, 2022 /PRNewswire/ -- Verseon is pleased to announce the appointment of its new CTO, Dr. Sangtae (Sang) Kim.
  • Sang, a member of the US National Academy of Engineering , will spearhead expansion of the company's data-science and AI initiatives.
  • Sang's engineering and data-science expertise will both complement and expand Verseon's already significant technological advantages in computer-driven drug design.
  • In recent years he has started research initiatives to use AI for multiple aspects of drug design and development.

In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules , 2020-2030

Retrieved on: 
Tuesday, March 24, 2020
Health sciences, Drug discovery, Pharmaceutical sciences, Health, In silico, Drug design, Small molecule, Computational Resource for Drug Discovery, Verseon

Over time, the complexities of drug discovery, have increased; this is especially true for large molecules, which are inherently more complex than conventional small molecule drugs.

Key Points: 
  • Over time, the complexities of drug discovery, have increased; this is especially true for large molecules, which are inherently more complex than conventional small molecule drugs.
  • Currently, there are several in silico approaches available for the drug discovery process alone, such as structure based drug design, fragment based drug discovery and ligand based drug discovery.
  • The "In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery, Interface Based Drug Discovery Approaches)" report features an extensive study on the current landscape and the likely future potential of the companies offering services for the discovery of large molecule drugs based on the use of in silico tools and techniques.
  • A detailed analysis assessing the current opportunity within in silico drug discovery services market, comparing the number of pipeline products and current market size across different types of large molecules, and the availability and capabilities of affiliated in silico drug discovery service providers.